Background and Purpose-In
O bservational epidemiological studies show that low highdensity lipoprotein cholesterol (HDL-C) levels are independently associated with an increased risk of cardiovascular disease. 1.2 In addition, HDL-C remains a strong predictor of cardiovascular disease risk in statin-treated individuals who have reached their target low-density lipoprotein cholesterol (LDL-C) levels. 3, 4 It is less clear whether raising HDL-C levels can reduce this residual risk, although preliminary data and meta-analyses of data from the early niacin trials used to raise HDL-C before the widespread use of statins suggested this potential. [5] [6] [7] [8] [9] Because niacin also reduces LDL-C, it is not clear whether these benefits were caused by the effects of raising HDL-C or lowering LDL-C. Recently, dalcetrapid, a cholesteryl ester transfer protein inhibitor that raises HDL-C by 31% to 40% without further changes in low LDL-C levels, had no effect in reducing clinical outcomes, including coronary heart disease (CHD) or stroke in >13 000 subjects with acute coronary syndrome (ACS).
The Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial tested whether extended-release niacin (ERN) added to intensive statin (combination) therapy, compared with statin therapy alone (monotherapy), would reduce the risk of cardiovascular events in individuals with established atherosclerotic cardiovascular disease and atherosclerotic dyslipidemia (low HDL-C and elevated triglycerides). 11, 12 On April 25, 2011, at a planned interim analysis, the trial's Data and Safety Monitoring Board recommended that the blinded intervention be stopped 18 months earlier than planned, because of futility for the composite primary end point. Also of concern was an unexpected higher rate of ischemic stroke among participants allocated to ERN-statin combination therapy. 13 The latter assessment was preliminary and based on incomplete outcome event adjudication in the interim report. The objective of this final analysis was to further examine AIM-HIGH data related to the risk of ischemic stroke after complete event ascertainment had been performed.
Methods
The design, organization, and baseline data of the AIM-HIGH study, an investigator-initiated trial approved and sponsored by the National Heart, Lung, and Blood Institute, have been described previously. 11, 13 The study was reviewed and approved by the institutional review boards of each of the 92 US and Canadian enrolling sites, and signed informed consent was obtained from each participant. Enrolled participants were ≥45 years of age and had established cardiovascular disease defined by documented stable CHD (previous history of myocardial infarction [MI] or documented multivessel coronary artery disease by angiography), cerebrovascular or carotid disease, or peripheral arterial disease (Table 1 ). All participants had low baseline levels of HDL-C (<1.0 mmol/L [40 mg/dL] for men; <1.4 mmol/L [50 mg/dL] for women) and elevated triglycerides (1.1-4.5 mmol/L [150-400 mg/dL]). For the 6% of participants who were not on a statin at entry, LDL-C was <4.7 mmol/L (180 mg/dL). Participants were required to discontinue lipid-modifying drugs, except for statins or ezetimibe, ≥4 weeks before randomization and had a fasting lipid profile meeting inclusion criteria, verified by the core laboratory. Potential participants were excluded if, within 4 weeks of enrollment, they had been hospitalized for an ACS, had a planned coronary revascularization, or had a stroke within the preceding 8 weeks. Exclusion criteria have been reported previously.
11,13
Intervention Individuals randomized to combination therapy were to receive simvastatin plus ERN 1500 to 2000 mg/d, whereas those randomized to monotherapy received matching placebo containing a small (50 mg) dose of immediate-release niacin in each tablet of 500 mg or 1000 mg placebo to mask the identity of blinded treatment to participants and study personnel. Both treatment arms received simvastatin, with the dose adjusted to an on-treatment LDL-C level of 1.0 to 2.2 mmol/L (40-80 mg/dL). To achieve and maintain a similar LDL-C target level in both treatment groups, subjects in either arm could also receive ezetimibe 10 mg/d, as needed. Only LDL-C levels were reported to clinical sites to maintain therapy masking.
13

Study Outcomes
The primary trial outcome was the composite of first occurrence of CHD death, nonfatal MI, ischemic stroke, hospitalization for ACS, or symptom-driven coronary or cerebral revascularization. Ischemic stroke was a component of several secondary composite outcomes that included the following: CHD death, nonfatal MI, ischemic stroke, or hospitalization for ACS and cardiovascular mortality. Tertiary outcomes included total mortality, individual components of the primary end point, and the effects of treatment on prespecified subgroups defined by sex, history of diabetes mellitus, and metabolic syndrome. 11, 13 An ischemic stroke was defined as an acute vascular event with focal neurological signs lasting >24 hours, without evidence of primary intracranial hemorrhage. A transient ischemic attack (TIA) was defined as having focal symptoms of a presumed ischemic basis lasting <24 hours. Imaging was not required (if imaging was performed and showed an area of ischemic injury, the event was adjudicated as a TIA if symptoms and signs lasted <24 hours). Hemorrhagic stroke was defined as an acute neurological vascular event with focal neurological signs lasting >24 hours or sudden severe headache and meningeal signs and evidence of intracranial hemorrhage by neuroimaging or autopsy. An acute neurological vascular event that fulfilled the definition of stroke, with focal neurological signs lasting >24 hours or sudden severe headache followed rapidly by coma, but without neuroimaging or autopsy data to classify into either an ischemic or hemorrhagic stroke, was considered as a primary stroke end point event.
A Clinical Events Committee, masked to the identity of treatment and included 3 board-certified university-based vascular neurologists, reviewed suspected primary outcomes (including silent MI) with supporting documentation. ECGs were centrally interpreted; all lipid and serum chemistry analyses were performed by a central laboratory. All neurological events were reviewed by 2 of the 3 neurologists. Consensus was reached if there were no disagreements after the primary adjudication. At study termination and after database lock, all neurological events that had not been originally classified as strokes were readjudicated by the still blinded Clinical Events Committee. The process was performed to distinguish TIA events from those reported as neurological events initially classified by the Clinical Events Committee as no neurological event.
Statistical Analyses
All analyses were performed using the intention-to-treat approach. Events adjudicated as ischemic stroke, hemorrhagic stroke, or TIA were included. Analyses of stroke end points, individually and in combination, were performed using time-to-event methods. KaplanMeier methods were used to estimate stroke rates, and Cox proportional hazard models were used to estimate hazard ratios (HR), confidence intervals (CI), and adjusted Wald statistics for stroke end points. Cox models were used to test for interactions between randomization assignment and known risk factors for stroke, including ≈20% of participants who had a prior stroke, and characterize the relationship between lipids and stroke without considering randomization assignment. Time-dependent Cox Models were used to adjust for time on and off niacin/placebo. Models were adjusted for age (≥65 versus <65 years) at randomization. A stepwise Cox model was used to identify factors independently associated with a given end point. Two-sided P<0.05 were considered statistically significant, with no adjustments for multiple statistical testing.
Results
Subject characteristics, study and concomitant drug therapy, and main outcomes of the AIM-HIGH trial have been reported in detail previously.
13 Table 1 summarizes pertinent baseline demographic and clinical characteristics, medications, and both lipid and lipoprotein levels for the 3414 subjects enrolled in the trial, of whom 1696 were randomized to statin plus placebo (monotherapy) and 1718 to statin plus ERN (combination therapy). All baseline characteristics were balanced between the 2 treatment groups.
At a mean 36-month follow-up, the composite primary outcome (death from CHD, nonfatal MI, ischemic stroke, hospitalization for ACS, or symptom-driven coronary or cerebral revascularization) occurred in 274 (16.2%) of those randomized to monotherapy and 282 (16.4%) randomized to combination
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October 2013 therapy. 13 There was no difference between the treatment groups in the primary outcome, which included 15 ischemic strokes in the monotherapy group and 27 in the combination group in the intention-to-treat analysis (HR, 1.02; 95% CI, 0.87-1.21; P=0.80). 13 Rereview of the previous TIA nonstroke neurological events by the Clinical Events Committee identified an additional 3 ischemic stroke events. A total of 50 ischemic strokes that occurred during the trial, including 5 ischemic strokes that did not qualify as primary study events because they occurred after one of the other events in the time-to-first event in the primary composite end point, were identified (total of 18 [1.06%] fatal or nonfatal ischemic strokes in the monotherapy group and 32 [1.86%] in the combination group). This number also included 8 strokes that occurred 2 months to 4 years after subjects had discontinued ERN therapy. Of the 50 fatal or nonfatal ischemic strokes, there were an excess number of events in the statin-ERN combination group (HR, 1.78; 95% CI, 1.00-3.17; P=0.050; Figure) . There were 7 hemorrhagic strokes and 30 TIAs among participants. The HR for the composite ischemic strokes and TIA was 1.20 (95% CI, 0.77-1.88; P=0.428). Table 2 summarizes the stroke events, composite stroke events, and the HRs comparing monotherapy and combination therapy. Table 3 shows the univariate associations between baseline parameters and the risk of ischemic stroke, which were significant only for age and a history of prior stroke. The 20% of participants with a history of cerebrovascular disease (stroke/ TIA/carotid disease) were at higher risk for ischemic stroke after adjusting for age and randomization assignment (HR, 2.08; 95% CI, 1.17-3.68; P=0.013), but there was no interaction between history of cerebrovascular disease and treatment group (data not shown).
The previous use of niacin or baseline use of statin, aspirin, or other antiplatelet agents, angiotensin-converting inhibitors, angiotensin receptor blockers, or any blood pressure-lowering drugs, a history of diabetes mellitus or MI, and the presence of hypertension, atrial fibrillation, or the metabolic syndrome were not associated with an increased risk of ischemic stroke (Table 3) .
There was no association between baseline lipids and stroke with the exception of elevated Lp(a), with higher Lp(a) levels associated with higher stroke risk (overall P=0.044, comparing highest versus lowest tertiles and middle versus lowest tertiles; Table 3 ). There were no significant associations between the mean lipid levels over time during the study and ischemic stroke risk (Table 4) .
Multivariate stepwise regressions analyses showed independent associations between ischemic stroke risk and ≥65 years of age (HR, 3.58; 95% CI, 1.82-7.05; P=0.0002), a history of stroke/TIA/carotid disease (HR, 2.18; 95% CI, 1.23-3.88; P=0.0079), and elevated baseline Lp(a) (HR, 2.80; 95% CI, 1.25-6.27 comparing the middle with the lowest tertile and HR, 2.31; 95% CI, 1.00-5.30 comparing the highest with the lowest tertile; overall P=0.042) but a nonsignificant association between ischemic stroke and combination therapy (HR, 1.74; 95% CI, 0.97-3.11; P=0.063; Table 5 ). Similar associations are observed when the composite outcome of ischemic stroke and TIA was used in the analysis (Table 5) .
Discussion
There was no prior published evidence of an increased risk of ischemic stroke associated with niacin, in combination with statin therapy. The initial observation at the meeting of the Data Safety and Monitoring Board on April 25, 2011, that combination treatment with ERN-statin might be associated with an excess of ischemic stroke was a concern. This analysis, however, was based on preliminary data. In the final analysis based on all finally adjudicated events, there remained an excess number of ischemic strokes associated with addition of ERN to simvastatin compared with simvastatin alone, but there was only a trend toward higher risk in the multivariable analysis. Although not significant, an increased risk with the addition of ERN to statin cannot be completely excluded, given the wide CI owing to the relatively small number of outcome events. There was also a nonsignificant numeric imbalance in the total adjudicated TIA events in the study, with 19 of the 30 occurring in the statin monotherapy group. Because TIA has pathophysiological similarities to ischemic stroke, if the combination therapy was truly harmful, the composite end point, including both ischemic stroke and TIA, would be expected to accentuate the risk, which was not observed. There were few hemorrhagic strokes and no significant differences between treatment groups for these events.
No previous studies or meta-analyses have found an increased incidence of stroke with niacin in any therapeutic formulation, dose, or dosing regimen. Previous trials [5] [6] [7] [8] [9] performed since the 1970s before the introduction of statin therapy were all small, except for the Cholesterol Drug Project (CDP) trial. This latter trial reported a significant 25% stroke reduction in subjects randomized to niacin compared with placebo (8.5% versus 11.2%, respectively; odds ratio [OR], 0.75; 95% CI, 0.59-0.92). 5, 6 A prior meta-analysis of these 10 trials evaluating the effects of niacin on clinical outcomes involving 6545 participants found that treatment was associated with a 25% reduction in major coronary events, a 26% reduction in stroke, and a 27% reduction of any cardiovascular event.
8 A more recent metaanalysis of 11 trials on ≈10 000 subjects, and which included AIM-HIGH plus many of the trials included in the earlier meta-analysis, reported that niacin was associated with significant reductions in composite end points of any cardiovascular disease event (OR, 0.66; 95% CI, 0.49-0.89; P=0.007) and in major CHD events (OR, 0.75; 95% CI, 0.59-0.96; P=0.02) but no significant association between niacin therapy and stroke incidence (OR, 0.88; 95% CI, 0.50-1.54; P=0.65). 9 There are major differences in background therapy and baseline and on-treatment lipid levels between prior trials and 2 recent studies. For example, baseline total cholesterol levels in the CDP trial were ≈250 mg/dL (6.5 mmol/L), with an ontreatment level of ≈225 mg/dL (5.8 mmol/L). These levels were much higher than the baseline and on-treatment levels in AIM-HIGH. 12, 13 In AIM-HIGH, all participants received intensive statin therapy to reduce their LDL cholesterol levels to 1.0 to 2.2 mmol/L (40-80 mg/dL). Similarly, in the recently reported Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2--THRIVE) randomized placebo-controlled trial of ERN combined with laropiprant in 25 673 participants with preexisting cardiovascular disease, all of whom received LDL-lowering therapy with simvastatin 40 mg daily with or without ezetimibe, baseline total cholesterol was 128 mg/dL (3.32 mmol/L).
14 Both AIM-HIGH and the much larger HPS2-THRIVE showed that the addition of niacin was not associated with reductions in vascular events, including no reduction in stroke. HPS2-THRIVE is a large trial, in which participants were followed for 4 years and during which 804 ischemic strokes occurred. This would have been adequately powered to detect specific clinical end points, such as stroke. That this trial did not show an excess of ischemic stroke suggests that there is little risk of excess ischemic stroke with niacin therapy. The addition of niacin may have resulted in little, if Figure. Kaplan-Meier curves for ischemic stroke comparing statin monotherapy with extended-release niacin-statin combination therapy. Included nonfatal and fatal strokes, including 5 which were not counted in the primary composite end points of the trial because these occurred after another event which was counted. CI indicates confidence interval; and HR, hazard ratio. any, reduction of cardiovascular events in the more recent trials because of the lower LDL-C levels due to statin therapy. We also explored the effects of known factors that could influence the risk for ischemic stroke in the AIM-HIGH data set. Older age and a history of stroke/TIA/carotid disease are established risk factors for first or recurrent stroke and were found to be independently associated with an increased risk of ischemic stroke in AIM-HIGH, regardless of treatment assignment. There was a moderate association between Lp(a) and ischemic stroke comparing the lowest with the middle tertile and the lowest with the highest tertile of Lp(a) levels. These results were consistent with the Emerging Risk Factors Collaboration investigators report, with pooled data from 36 prospective studies on 126 634 participants, and concluded that there were continuous, independent, and modest associations of increasing Lp(a) concentration with increased risk of CHD and stroke. 15 In our further exploratory analyses in AIM-HIGH, there were more events in the middle tertile than in the highest tertile of Lp(a) levels. This observation is likely because of chance, given the small numbers of events. There was also a significant interaction between Lp(a) distribution and treatment assignment on ischemic stroke risk in multivariate analysis. The risk of ischemic stroke with ERNstatin combination therapy compared with simvastatin alone tended to be lower in participants in the lowest (HR, 0.62; 95% CI, 0.15-2.60) and highest tertiles of Lp(a) (HR, 0.76; 95% CI, 0.30-1.94) but increased in those in the middle tertile (HR, 6.95; 95% CI, 2.06-23.38), P value for interaction 0.008. There is no plausible reason for this finding, which may also have been because of chance.
Other factors that may influence the risk of ischemic stroke, including previous niacin or statin therapies, background trial therapies with aspirin or other antiplatelet agents, inhibitors of the renin-angiotensin system, or any blood pressure-lowering agents, history of diabetes mellitus, previous CHD, hypertension, atrial fibrillation, or metabolic syndrome, and other baseline lipid subfractions or lipoproteins, were not associated with an increased stroke risk in this study.
AIM-HIGH has several limitations. Although we enrolled 3414 participants with adequate sample size to detect a 25% reduction in the primary composite end point with 85% power between the treatments, the trial was neither designed nor powered to detect a treatment effect for each of the components of the composite primary end point. For ischemic stroke, the event rate of 0.5 events/y was comparable with the 0.5 events/y reported by the Cholesterol Treatment Trialists' Collaboration in the group of participants who received intensive statin 16 However, with such a low incidence and only 3 years of follow-up, the trial was not adequately powered to detect a difference in long-term treatment effect even if one existed. The absence of excess ischemic stroke risk in the larger HPS2-THRIVE trial further lowers the possibility of this risk being real. The number of hemorrhagic strokes and TIAs was too few to provide adequate power for an analysis of a potential treatment effect. In previous trials of niacin, particularly the CDP trial, baseline LDL-C levels were much higher and participants were not treated with a statin. The benefit of niacin may be limited to individuals with poorly controlled LDL-C levels. Although it is not possible to exclude the possibility that niacin might in some way interfere with the effects of the statin, there is no pharmacological basis for such an interaction.
Conclusions
Although there was a numeric excess in ischemic strokes associated with the addition of niacin to simvastatin, the number of events was small, and multivariate analysis accounting for known risk factors did not support a significant association between niacin and ischemic stroke risk. 
